Clinical trial
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations…
NCT00233064 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00233064 |
|---|---|
| Title | Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) |
| Official title | A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Lung Disease |
| Intervention type | Biological |
| Interventions | Lyophilized Palivizumab, Liquid Palivizumab |
| Enrollment | 417 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Oct 5, 2005 |
| Last update posted | Jun 27, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: